Valuation : Lupin Limited

Market Cap 976B 10.33B 8.89B 8.34B 7.63B 14.24B 14.35B 98.64B 38.41B 499B 38.78B 37.93B 1,607B P/E 2027 *
22.2x
P/E 2028 * 20.9x
Enterprise Value 933B 9.87B 8.49B 7.97B 7.29B 13.61B 13.71B 94.26B 36.71B 477B 37.06B 36.25B 1,535B EV / Sales 2027 *
3.08x
EV / Sales 2028 * 2.79x
Free-Float
52.98%
Yield 2027 *
0.59%
Yield 2028 * 0.6%
1 day-0.82%
1 week-2.56%
Current month-1.97%
1 month-11.56%
3 months-5.09%
6 months-7.64%
Current year+1.09%
1 week 2,135
Extreme 2135
2,209
1 month 2,135
Extreme 2135
2,426.65
Current year 2,072.95
Extreme 2072.95
2,530
1 year 1,900.3
Extreme 1900.3
2,530
3 years 1,091.8
Extreme 1091.8
2,530
5 years 583.05
Extreme 583.05
2,530
10 years 505
Extreme 505
2,530
Manager TitleAgeSince
Chief Executive Officer 58 01/09/2013
Director of Finance/CFO 61 13/08/2007
Compliance Officer - 01/09/2024
Director TitleAgeSince
Director/Board Member 52 08/10/2008
Director/Board Member 58 01/01/1997
Chairman 83 11/08/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%-2.56%+13.03%+95.28% 10.42B
-0.04%-2.51%+57.73%+108.15% 1,034B
+1.17%+3.12%+56.37%+73.50% 663B
-0.58%-1.02%+22.79%+75.58% 462B
+2.09%-3.20%+36.07%+37.41% 344B
0.00%+3.26%+29.76%+46.97% 307B
+1.42%-0.72%+2.03%+13.51% 251B
+0.29%+0.86%+54.79%+73.00% 239B
-0.03%-1.11%-15.87%-53.65% 207B
+1.08%+2.11%+34.17%+97.29% 186B
Average +0.52%-0.80%+29.09%+56.70% 370.38B
Weighted average by Cap. +0.63%-0.84%+39.41%+67.94%

Financials

2027 *2028 *
Net sales 303B 3.2B 2.76B 2.59B 2.37B 4.42B 4.45B 30.61B 11.92B 155B 12.03B 11.77B 499B 322B 3.41B 2.93B 2.75B 2.52B 4.7B 4.73B 32.54B 12.67B 165B 12.79B 12.51B 530B
Net income 43.97B 465M 400M 376M 344M 641M 646M 4.44B 1.73B 22.47B 1.75B 1.71B 72.37B 46.7B 494M 425M 399M 365M 681M 687M 4.72B 1.84B 23.87B 1.86B 1.81B 76.86B
Net Debt -43.31B -458M -394M -370M -338M -632M -637M -4.38B -1.7B -22.13B -1.72B -1.68B -71.28B -77.92B -824M -709M -665M -609M -1.14B -1.15B -7.87B -3.07B -39.82B -3.1B -3.03B -128B
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
26,021
Date Price Change Volume
03/09/26 2,135.00 -0.82% 136,989
02/09/26 ₹2,152.60 +0.12% 237,462
01/09/26 ₹2,150.00 -1.29% 15,860
31/08/26 ₹2,178.00 +0.14% 25,043
28/08/26 ₹2,175.00 +0.48% 15,828
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
2,135.00INR
Average target price
2,490.58INR
Spread / Average Target
+16.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUPIN Stock